Merck enters into $2.5bn oncology deal with Taiho and Astex

This article was originally published here

Under an exclusive worldwide research collaboration and licence agreement, the companies will be engaged in the development of small molecule inhibitors against several drug targets, which include the

The post Merck enters into $2.5bn oncology deal with Taiho and Astex appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply